About the EBV gH/gL Protein Complex

The Epstein-Barr virus (EBV, Human Herpesvirus 4) gH/gL protein complex is a critical component of the viral fusion machinery required for infection of both epithelial cells and B lymphocytes. Glycoprotein H (gH) and glycoprotein L (gL) form a conserved heterodimer that functions together with glycoprotein B (gB) to mediate membrane fusion during viral entry. Because gH/gL is essential for EBV infectivity, it has become one of the most important targets for vaccine development, neutralizing antibody discovery, and antiviral therapeutic research.

The gH/gL complex participates in receptor recognition and activation of the viral fusion process, enabling EBV to enter susceptible host cells. Numerous studies have demonstrated that antibodies directed against gH/gL can effectively block viral entry and neutralize EBV infection in both epithelial cells and B cells. As a result, gH/gL is widely recognized as a promising immunogen for next-generation EBV vaccines and antibody-based therapeutics.

eEnzyme's recombinant EBV gH/gL Protein Complex is expressed in HEK293 cells and is suitable for viral entry studies, vaccine development, antibody screening, receptor-binding analysis, structural biology investigations, and immunological assay development. The protein complex provides a valuable tool for researchers investigating EBV pathogenesis, viral fusion mechanisms, and host immune responses.

Applications of the EBV gH/gL Protein Complex

• Neutralizing antibody discovery and characterization
• EBV vaccine development research
• Viral entry and membrane fusion studies
• Receptor-binding investigations
• Structural biology and epitope mapping
• ELISA, Western blot, and immunological assays

Biological Significance of the gH/gL Complex

The EBV gH/gL heterodimer functions as a central regulator of viral membrane fusion. During infection, gH/gL cooperates with glycoprotein B (gB) to facilitate fusion of the viral envelope with host-cell membranes. Because this complex is required for infection of multiple cell types and is a major target of protective neutralizing antibodies, gH/gL remains a key focus of EBV vaccine, therapeutic antibody, and antiviral drug development programs.